Key Melanoma Trials at ASCO Yield Encouraging Survival Data Key Melanoma Trials at ASCO Yield Encouraging Survival Data

The survival advantage seen in the COLUMBUS trial with a BRAF/MEK drug combination may be unprecedented, says Dr Jeffrey Weber.Medscape Oncology
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news